Literature DB >> 7808478

Molecular characterization of a 65-kilodalton Toxoplasma gondii antigen expressed abundantly in the matrix of tissue cysts.

S F Parmley1, S Yang, G Harth, L D Sibley, A Sucharczuk, J S Remington.   

Abstract

We describe the cloning and characterization of a novel antigen expressed in the bradyzoite stage of Toxoplasma gondii. A cDNA library was constructed in bacteriophage lambda gt11 Sfi-Not using messenger RNA molecules isolated from cysts of the ME49 strain of T. gondii. The recombinant phage library was subjected to screening with polyclonal antibodies against bradyzoite antigens. This screening identified a recombinant antigen that was recognized strongly by polyclonal antibodies against bradyzoite antigens as well as by sera from mice chronically infected with T. gondii. The native antigen is a protein of 65 kDa that localized to the matrix of the cyst and the cyst wall surrounding the bradyzoites. The antigen was found to be expressed abundantly in cysts but could not be detected in tachyzoites or within the parasitophorous vacuole of tachyzoite infected host cells. Genomic and cDNA sequence of the gene revealed an open reading frame encoding 452 amino acids interrupted by 2 introns: a 503-bp intron located in the 5' untranslated region preceding the protein coding sequence and a 110-bp intron located 95 bp downstream of the first ATG.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7808478     DOI: 10.1016/0166-6851(94)90155-4

Source DB:  PubMed          Journal:  Mol Biochem Parasitol        ISSN: 0166-6851            Impact factor:   1.759


  30 in total

Review 1.  The development and biology of bradyzoites of Toxoplasma gondii.

Authors:  L M Weiss; K Kim
Journal:  Front Biosci       Date:  2000-04-01

2.  Disruption of the Toxoplasma gondii bradyzoite-specific gene BAG1 decreases in vivo cyst formation.

Authors:  Y W Zhang; K Kim; Y F Ma; M Wittner; H B Tanowitz; L M Weiss
Journal:  Mol Microbiol       Date:  1999-01       Impact factor: 3.501

3.  Toxoplasma gondii asexual development: identification of developmentally regulated genes and distinct patterns of gene expression.

Authors:  Michael D Cleary; Upinder Singh; Ira J Blader; Jeremy L Brewer; John C Boothroyd
Journal:  Eukaryot Cell       Date:  2002-06

4.  Use of MAG1 recombinant antigen for diagnosis of Toxoplasma gondii infection in humans.

Authors:  Lucyna Holec; Elzbieta Hiszczyńska-Sawicka; Artur Gasior; Anna Brillowska-Dabrowska; Józef Kur
Journal:  Clin Vaccine Immunol       Date:  2007-01-03

5.  Bradyzoite development in Toxoplasma gondii and the hsp70 stress response.

Authors:  L M Weiss; Y F Ma; P M Takvorian; H B Tanowitz; M Wittner
Journal:  Infect Immun       Date:  1998-07       Impact factor: 3.441

6.  Expressed sequence tag analysis of the bradyzoite stage of Toxoplasma gondii: identification of developmentally regulated genes.

Authors:  I D Manger; A Hehl; S Parmley; L D Sibley; M Marra; L Hillier; R Waterston; J C Boothroyd
Journal:  Infect Immun       Date:  1998-04       Impact factor: 3.441

7.  Bradyzoite pseudokinase 1 is crucial for efficient oral infectivity of the Toxoplasma gondii tissue cyst.

Authors:  Kerry R Buchholz; Paul W Bowyer; John C Boothroyd
Journal:  Eukaryot Cell       Date:  2013-01-04

8.  Seroreactivity to and avidity for recombinant antigens in toxoplasmosis.

Authors:  Klaus-Ingmar Pfrepper; Gisela Enders; Marion Gohl; Doris Krczal; Harald Hlobil; Doris Wassenberg; Erwin Soutschek
Journal:  Clin Diagn Lab Immunol       Date:  2005-08

9.  The Toxoplasma MAG1 peptides induce sex-based humoral immune response in mice and distinguish active from chronic human infection.

Authors:  Jianchun Xiao; Raphael P Viscidi; Geetha Kannan; Mikhail V Pletnikov; Ye Li; Emily G Severance; Robert H Yolken; Laurence Delhaes
Journal:  Microbes Infect       Date:  2012-11-07       Impact factor: 2.700

10.  Requirement of non-T cells that produce gamma interferon for prevention of reactivation of Toxoplasma gondii infection in the brain.

Authors:  H Kang; Y Suzuki
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.